RAMM Pharma Corp.
RAMM
CNSX
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -42.32% | -24.89% | -17.66% | -13.41% | -8.23% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -42.32% | -24.89% | -17.66% | -13.41% | -8.23% |
| Cost of Revenue | -32.56% | -5.07% | -28.58% | -42.08% | -40.93% |
| Gross Profit | -56.99% | -53.59% | 60.80% | 414.75% | 448.95% |
| SG&A Expenses | -48.87% | -47.63% | 4.39% | 13.01% | 34.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -35.69% | -34.79% | -12.26% | -16.19% | -18.12% |
| Total Operating Expenses | -45.26% | -38.77% | -7.25% | -7.62% | 5.20% |
| Operating Income | 46.88% | 46.14% | 0.44% | 3.87% | -14.46% |
| Income Before Tax | 44.86% | 47.19% | -47.71% | -51.76% | -81.39% |
| Income Tax Expenses | 229.53% | 84.75% | 28.17% | 28.17% | -901.41% |
| Earnings from Continuing Operations | 43.92% | 47.12% | -47.68% | -51.73% | -80.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 43.92% | 47.12% | -47.68% | -51.73% | -80.26% |
| EBIT | 46.88% | 46.14% | 0.44% | 3.87% | -14.46% |
| EBITDA | 47.41% | 47.69% | -8.32% | -1.86% | -24.31% |
| EPS Basic | 43.88% | 47.14% | -47.45% | -51.63% | -80.62% |
| Normalized Basic EPS | 39.19% | 41.90% | 13.60% | 8.03% | -17.93% |
| EPS Diluted | 43.88% | 47.14% | -47.45% | -51.63% | -80.62% |
| Normalized Diluted EPS | 39.19% | 41.90% | 13.60% | 8.03% | -17.93% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.01% | -0.26% | -0.76% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.01% | -0.26% | -0.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |